Quantcast

Latest Haemophilia Stories

2014-04-17 12:30:37

DUBLIN, April 17, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fclw7g/global_hemophilia) has announced the addition of the "Global Hemophilia Market 2014-2018" [http://www.researchandmarkets.com/research/fclw7g/global_hemophilia ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Hemophilia market to grow at a CAGR of 6.07 percent over the period...

2014-04-17 08:28:45

- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries BARCELONA, Spain, April 17, 2014 /PRNewswire/ -- Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) today announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a...

2014-04-17 08:28:23

Donated coagulation factor supports WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 17, 2014 /PRNewswire/ -- CSL Behring announced today that the company will continue its ongoing commitment to the global coagulation disorders community with a donation of product to the World Federation of Hemophilia (WFH). The donation, provided in connection with World Hemophilia Day on April 17, supports WFH's Global Alliance for Progress (GAP) program aimed at improving the...

2014-04-17 08:22:44

Inspirational video is launched on World Hemophilia Day to tell the story of one Canadian's triumph over adversity TORONTO, April 17, 2014 /CNW/ - Attitude makes you a hero; that's why John Schmitke, Vice President and Chairman of the Youth Committee at the Canadian Hemophilia Society, Manitoba Chapter, is working to empower and inspire those with hemophilia by sharing his own positive approach to living with this blood disorder. On World Hemophilia Day (April 17, 2014), John...

2014-04-16 16:26:40

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_hemophilia_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022SummaryThe competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of...

2014-04-16 08:32:37

6.9 million people have a bleeding disorder. 75 percent of them don't know it. MONTREAL, April 16, 2014 /PRNewswire/ -- Every year on April 17, World Hemophilia Day is observed around the world to increase awareness of hemophilia and other inherited bleeding disorders. In 2014, World Hemophilia Day's theme will encourage the younger generation of the global bleeding disorders community to "Speak out. Create change." "World Hemophilia Day is part of our critical effort to aid in...

2014-03-24 12:25:01

KING OF PRUSSIA, Pa., March 24, 2014 /PRNewswire/ -- Navigating the complexities of the Affordable Healthcare Act (ACA) can be challenging, particularly where patients with chronic medical disorders such as hemophilia and von Willebrand disease are concerned. CSL Behring is awarding a Local Empowerment for Advocacy Development (LEAD) grant to help bleeding disorder patients develop a clearer understanding of ACA and potential areas of concern....

2014-03-24 08:28:01

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ - Biogen Idec (NASDAQ: BIIB) has announced that Health Canada approved ALPROLIX((TM) )[Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and...

2014-02-20 08:30:34

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of...

2014-02-18 04:21:07

- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb. 18, 2014 /PRNewswire/ -- Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related